Avantor Results Presentation Deck

Summary Strong business momentum Robust revenue, earnings and cash flow results Strong growth in core business, across all geographies, industries and products Rapid deleveraging continues, supports ongoing M&A - - Executing on our growth strategy Continued focus on proprietary growth through Biopharma platform Investment in core capabilities to sustain long-term growth Closed on two M&A transactions - Looking ahead - - Attractive industry exposure, favorable conditions across all end markets Raising guidance for all financial metrics for FY21 Balance sheet strength provides considerable M&A capacity avantor™ VIRTUAL INVESTOR DAY September 9, 2021 9:00am - 12:00pm EDT Register on Avantor's Investor Relations website https://ir.avantorsciences.com/investors/ 10

View entire presentation